Results 101 to 110 of about 2,740,979 (275)

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Chagas disease cardiomyopathy: current concepts of an old disease Cardiomiopatia chagásica: conceitos atuais de doença antiga

Revista do Instituto de Medicina Tropical de São Paulo, 2008
Chagas disease continues to be a significant public health problem, as ca. 10 million people are still infected with T. cruzi in Latin America. Decades after primary infection, 30% of individuals can develop a form of chronic inflammatory cardiomyopathy ...
Angelina M.B. Bilate, Edecio Cunha-Neto
doaj   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

About so called “inflammatory cardiomyopathy” [PDF]

, 2005
According to the latest literature data, the authors analyze pathogenesis of viral myocardial impairment, leading to pathological complex process, called “viral myocarditis”.
S. R. Mravyan, M. A. Gurevich
core  

Myocarditis and inflammatory cardiomyopathy: current evidence and future directions

, 2020
Inflammatory cardiomyopathy, characterized by inflammatory cell infiltration into the myocardium and a high risk of deteriorating cardiac function, has a heterogeneous aetiology.
Heymans, Stephane, Cooper, L.T., Heidecker, Bettina, Starling, Randall C, Parwani, Abdul S., Caforio, Alida L.P., Tschoepe, Carsten, Caforio, Alida L. P., Hare, Joshua M., Spillmann, Frank, Hare, J.M., Klingel, K., Felix, S.B., Heidecker, B., Parwani, A.S., Caforio, A.L.P., Ammirati, Enrico, Starling, Randall C., Heymans, S., Hübner, N., Starling, R.C., Tschöpe, C., Tschöpe, Carsten, Cooper, Leslie T., Tsutsui, Hiroyuki, Tsutsui, H., Felix, Stephan B., Maatz, Henrike, Kelle, S., Bozkurt, Biykem, Hare, Joshua M, Ammirati, E., Felix, Stephan B, Klingel, Karin, Maatz, H., Parwani, Abdul S, Seferovic, P., Van Linthout, S., Seferovic, Petar, Van Linthout, Sophie, Caforio, Alida L P, Spillmann, F., Kelle, Sebastian, Bozkurt, B., Huebner, Norbert, Hübner, Norbert, Cooper, Leslie T, Sebastian Kelle, Stephane Heymans, Karin Klingel, Frank Spillmann, Abdul S. Parwani, Petar Seferovic, Norbert Hübner, Biykem Bozkurt, Carsten Tschöpe, Randall C. Starling, Joshua M. Hare, Sophie Van Linthout, Henrike Maatz, Bettina Heidecker, Enrico Ammirati, Leslie T. Cooper, Hiroyuki Tsutsui, Stephan B. Felix, Alida L. P. Caforio   +65 more
core   +1 more source

THE ROLE OF PARVOVIRUS B19 IN THE DEVELOPMENT OF INFLAMMATORY CARDIOMYOPATHY [PDF]

, 2015
The problem of inflammatory cardiomyopathy is discussed. The etiology, pathogenesis, diagnosis and treatment of inflammatory cardiomyopathy are considered with focus on the role of parvovirus ...
A. A. Skvortsov, S. N. Tereshchenko, A. Yu. Shchedrina, A. A. Safiullina, K. A. Zykov   +4 more
core   +1 more source

Takotsubo cardiomyopathy in cancer patients

Cardio-Oncology, 2019
Background Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM).
Aakash Desai, Arish Noor, Saurabh Joshi, Agnes S. Kim   +3 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Visual Abstract - Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy: 10.1016/j.jacbts.2016.04.005

, 2019
• Mice infected with T. cruzi control acute parasitemia but develop chronic chagasic cardiomyopathy.• Treatment with SIL (a phosphodiesterase inhibitor) during a therapeutic window of indeterminate phase provided powerful cardioprotective effects against
Nisha Jain Garg (6834830), John Thacker (6821051), Jian-jun Wen (3229983), Xianxiu Wan (101988)   +3 more
core   +1 more source